A major review challenges a long-standing strategy in Alzheimer’s research, suggesting that removing a hallmark brain protein ...

Amyloid-beta plaques can harm neurons in the brain. (Sebastian Kaulitzki/Science Photo Library/Getty Images) The list of ...

A new review of preclinical studies suggests GLP-1 drugs like Ozempic may reduce key proteins linked to Alzheimer’s disease.

An estimated 50 million people worldwide have dementia, with Alzheimer's disease—accounting for more than 70%—being the representative neurodegenerative brain disorder. A Korean research team has, for ...

Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new Cochrane review has ...

Amyloid beta is a peptide that plays a central role in the neurodegenerative pathology of Alzheimer’s disease by aggregating into plaques in the brain. U.S. Food and Drug Administration (FDA) approved ...

Drugs best known for helping people lose weight may also chip away at the proteins that define Alzheimer’s disease. A ...

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy transthyretin moves hormones through blood and spinal fluid, misfolded ...

Amyloid proteins are typically considered bad guys, playing front-and-center roles in diseases such as Alzheimer’s and Parkinson’s. However, for nearly two decades, the Stowers Institute in Kansas ...

Alzheimer's disease (AD) is a neurodegenerative disorder that leads to progressive memory loss and a decline in mental ...